1. High-tech biomedical industry advantage. The company has traditional Chinese medicine, chemical medicine, high-end medical equipment, three high-tech areas of core science and technology, in the national focus on the development of emerging industries. National 13th Five-Year Plan intends to 3.6 trillion yuan industry output value growth to 8 trillion yuan. This year, the World Association of Traditional Chinese Medicine branch presidents meeting held in China, will promote the globalization of Chinese medicine, ushering in a new opportunity for the development of Chinese medicine.
2. The company's fundamentals have been reversed. At present, it has developed into a high-tech pharmaceutical and health industry cluster spanning modern Chinese medicine, chemical medicine, biotechnology medicine, pharmaceutical excipients and APIs, medical devices, medical and health services and many other fields, integrating investment and financing, research and development, production and sales. The company completed a major reorganization, the company's reorganization has always been the stock to produce large fluctuations in the rise of the subject, but not only did not go up instead of lagging, there may be a delayed reaction. Since this year the company announced a number of new drugs for the treatment of coronary heart disease, its scientific and technological content, high value-added, widely used. Cardiovascular disease is currently the main killer of human death and health, cardiovascular disease and cancer is the cause of human death of the champion and runner-up, its mortality rate accounted for about 40%, 36% or so. The company produces a variety of drugs for the treatment of cardiovascular disease, the prospect is unlimited.
3. The low valuation of the market is remarkable. Announcement forecast Q1 quarterly earnings growth this year, 1.8 billion yuan, earnings per share of 0.06 yuan, the price-earnings ratio ll only 15 times more, which in the A-share technology stocks on average nearly 100 times more than the average pharmaceutical technology stocks 60 times more than the average is considered a low valuation, perhaps A-share pharmaceutical science and technology stocks in the valuation of the lowest. The absolute price of the stock is as low as 3 yuan or more can be listed as the lowest pharmaceutical technology stocks. Daily K-line chart is in the first big wave of the first wave of the third sub-wave of the initial section, is about to break through the third sub-wave of the fast-rising run. Weekly K line appeared rare eight consecutive weeks at the bottom of the volume and the stock price does not rise typical pressure plate sucking phenomenon, and the formation of a weekly rising channel, the weekly level of rebound will not be less than 1 times the rebound market.